Key Highlights

  • IQVIA (NYSE:IQV) reports before the open on Tuesday, October 27, 2026, with consensus adjusted earnings of USD 3.28 per share, a USD 34.2 billion backlog and 2026 guidance of USD 12.80 to USD 13.00 per share.
  • ICON (NASDAQ:ICLR) reports after the close the same day against consensus of USD 2.63 per share, with a USD 23.4 billion backlog and reaffirmed guidance of USD 10.00 to USD 11.00 per share.
  • Repligen (NASDAQ:RGEN) reports before the open against consensus of USD 0.46 per share, after raising 2026 organic growth guidance to 10.5% to 13.5% and adjusted earnings guidance to USD 2.03 to USD 2.09.
  • Nautilus Biotechnology (NASDAQ:NAUT) reports before the open against a consensus loss of USD 0.16 per share, with cash and investments of about USD 129.2 million, while the Federal Reserve decides on Wednesday, October 28, 2026.

IQVIA (NYSE:IQV): backlog conversion after a raised guide

IQVIA (NYSE:IQV) provides clinical trial services, health data and analytics to drug developers, and it reports third-quarter 2026 results before the open on Tuesday, October 27, 2026. Consensus adjusted earnings are USD 3.28 per share, USD 0.13 above the USD 3.15 reported for the second quarter. That quarter brought revenue of USD 4.368 billion, up 8.7% year on year, and adjusted EBITDA of USD 994 million, up 9.2%. Full-year guidance was raised to revenue of USD 17.275 billion to USD 17.475 billion and adjusted earnings of USD 12.80 to USD 13.00 per share. Results cannot be known in advance.

In the research and development segment, net new bookings rose 19% to USD 3.15 billion, a book-to-bill ratio of 1.22 times, meaning contracts signed exceeded revenue recognised. Contracted backlog stood at USD 34.2 billion, and about USD 9.2 billion is expected to convert to revenue over the next twelve months. The bull case is a book-to-bill ratio above 1.2 times and guidance lifted again, which would likely support the shares. The bear case is higher cancellations, slower conversion or tighter biotech funding, any of which could prompt a sharp fall in a stock priced for steady compounding.

ICON (NASDAQ:ICLR): bookings strong, conversion slow

ICON Public Limited Company (NASDAQ:ICLR) is an Ireland-based contract research organisation that runs clinical trials for drug and device developers, and it reports third-quarter results after the close on Tuesday, October 27, 2026. Consensus adjusted earnings are USD 2.63 per share. In its release of Wednesday, July 29, 2026, the company reported second-quarter revenue of USD 2,063.5 million, up 1.2%, adjusted earnings of USD 2.56 per share against USD 3.52 a year earlier, and adjusted EBITDA of USD 327.2 million, or 15.9% of revenue.

Gross bookings were USD 3,681 million, cancellations USD 562 million and net bookings USD 3,120 million, a net book-to-bill ratio of 1.51 and a backlog of USD 23.4 billion. The challenge is conversion, since revenue growth of 1.2% is slow relative to that backlog. The company reaffirmed revenue of USD 7,850 million to USD 8,150 million and adjusted earnings of USD 10.00 to USD 11.00 per share, a wide range for a USD 2.63 consensus. The bull case is cancellations below USD 562 million and a stable margin. The bear case is adjusted earnings below USD 2.50 or a lower end of the range, which would be read cautiously.

Repligen (NASDAQ:RGEN): orders and margins in bioprocessing

Repligen (NASDAQ:RGEN) supplies filtration, chromatography and analytics products used to make biological medicines, and it reports third-quarter results before the open on Tuesday, October 27, 2026. Consensus adjusted earnings are USD 0.46 per share, below the USD 0.54 delivered in the second quarter. In the company's release of Tuesday, July 28, 2026, revenue was USD 204.1 million, up 12% and 13% organic, and full-year revenue guidance was set at USD 813 million to USD 835 million. By simple arithmetic, the first half revenue of USD 398.4 million implies USD 414.6 million to USD 436.6 million in the second half.

Bioprocessing suppliers sell consumables that customers reorder as drug production runs, so revenue follows customer batch activity and the destocking cycle that followed the pandemic. Guidance includes a gross margin of 53.7% to 54.2% and excludes the pending acquisition of BioLife Solutions (NASDAQ:BLFS). The bull case is organic growth near the top of the range with margins held, which could lift the shares. The bear case is a slowdown in orders that makes the second-half revenue look demanding, or a cautious tone on integration and funding, which could lead to a sharp fall given the valuation attached to growth.

Nautilus Biotechnology (NASDAQ:NAUT): a pre-revenue tools name judged on cash

Nautilus Biotechnology (NASDAQ:NAUT) is developing a platform for measuring proteins, the molecules that carry out functions in cells, and it is scheduled to report before the open on Tuesday, October 27, 2026. Consensus calls for a loss of USD 0.16 per share, and a revenue consensus is not meaningful for a company with almost no sales. In the company's release of Tuesday, July 28, 2026, second-quarter revenue was about USD 0.2 million, the net loss was about USD 14.5 million and cash and investments were about USD 129.2 million. The company also adjusted its product roadmap alongside those results.

The shares reflect confidence in the technology and in the funding behind it. A quarterly net loss of about USD 14.5 million against USD 129.2 million of cash and investments implies a runway of roughly two years, which is simple arithmetic on two published figures and assumes spending stays level. The bull case is a loss at or below USD 0.16 with concrete technical progress, which could lift the shares by a high single-digit or double-digit percentage. The bear case is a wider loss, a further delay or an earlier need for funds.

Where Things Stand

The answer is that biopharma demand looks firm in orders but is not yet showing up in revenue growth, so each name needs to convert that demand into results. IQVIA (NYSE:IQV) needs a book-to-bill ratio near 1.2 times and a guidance range that holds, ICON (NASDAQ:ICLR) needs conversion of its USD 23.4 billion backlog, and Repligen (NASDAQ:RGEN) needs organic growth inside 10.5% to 13.5%. Nautilus Biotechnology (NASDAQ:NAUT) sits at the far end of the chain, where customer budgets and the cost of capital decide whether tools are bought.

The next catalysts are the IQVIA, Repligen and Nautilus releases before the open and the ICON release after the close on Tuesday, October 27, 2026, followed by the Federal Reserve decision on Wednesday, October 28, 2026, after the rate rise to a range of 3.75% to 4.00% on Wednesday, September 16, 2026. Consensus figures and guidance are estimates, not guarantees, and this is not investment advice.